Patents Represented by Attorney Louis V. Wollenberger
-
Patent number: 8318169Abstract: A biocompatible, sustained release intraocular drug delivery system comprising a protein or polynucleotide therapeutic agent, a polymeric carrier for the therapeutic agent and a long chain fatty alcohol release modifier. The biocompatible, sustained release intraocular drug delivery system can be used to treat an ocular condition.Type: GrantFiled: September 12, 2011Date of Patent: November 27, 2012Assignee: Allergen, Inc.Inventors: John T. Trogden, Robert T. Lyons
-
Patent number: 8318070Abstract: The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.Type: GrantFiled: September 1, 2011Date of Patent: November 27, 2012Assignee: Allergan, Inc.Inventors: Jane-Guo Shiah, Rahul Bhagat, Wendy M. Blanda, Thierry Nivaggioli, Lin Peng, David Chou, David A. Weber
-
Patent number: 8298570Abstract: Biocompatible intraocular implants include a steroid and a polymer associated with each other to facilitate release of the steroid into an eye for a period of time greater than about two months. The steroid may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants may be placed in an eye to treat one or more ocular conditions. The steroid is released from the implant for more than about two months, and may be release for more than several years.Type: GrantFiled: February 14, 2008Date of Patent: October 30, 2012Assignee: Allergan, Inc.Inventors: Glenn T Huang, Thierry Nivaggioli
-
Patent number: 8293741Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants can be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others or to improve vision in a normal eye.Type: GrantFiled: April 29, 2005Date of Patent: October 23, 2012Assignee: Allergan, Inc.Inventors: James A. Burke, Patrick M. Hughes, Kai-Ming Zhang, Ton Lin, Glenn Huang, Brittany A. Jackson, Larry A. Wheeler, Rosy S. Donn
-
Patent number: 8293210Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to prevent the occurrence of one or more ocular conditions, or to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like.Type: GrantFiled: October 29, 2007Date of Patent: October 23, 2012Assignee: Allergan, Inc.Inventors: Glenn T. Huang, James Burke, Patrick M. Hughes, Kai-Ming Zhang, Ton Lin, Larry A. Wheeler, Rosy Sheng Donn
-
Patent number: 8263110Abstract: Biocompatible intraocular implants include a steroid and a polymer associated with each other to facilitate release of the steroid into an eye for a period of time greater than about two months. The steroid may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants may be placed in an eye to treat one or more ocular conditions. The steroid is released from the implant for more than about two months, and may be release for more than several years.Type: GrantFiled: February 14, 2008Date of Patent: September 11, 2012Assignee: Allergan, Inc.Inventors: Glenn T Huang, Thierry Nivaggioli
-
Patent number: 8257730Abstract: Biocompatible intraocular implants include a steroid and a polymer associated with each other to facilitate release of the steroid into an eye for a period of time greater than about two months. The steroid may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants may be placed in an eye to treat one or more ocular conditions. The steroid is released from the implant for more than about two months, and may be release for more than several years.Type: GrantFiled: April 29, 2005Date of Patent: September 4, 2012Assignee: Allergan, Inc.Inventors: Glenn T. Huang, Thierry Nivaggioli, Lon T. Spada, Hiroshi Sugimoto, Wendy M Blanda, James N. Chang, Orest Olejnik
-
Patent number: 8252771Abstract: A biomaterial is disclosed having unique properties that make it useful in ocular drug delivery applications, where the drugs selected from the group consisting of a prostaglandin, a prostamide, a non-steroidal anti-inflammatory drug (NSAID), and a corticosteroid, and mixtures, derivatives, salts and esters thereof.Type: GrantFiled: January 31, 2008Date of Patent: August 28, 2012Assignee: Allergan, Inc.Inventors: Ronald E. Utecht, Kaia L. Kloster, Therese M. Downey, Barbara R. Haberer, Patrick D. Youso, James N. Chang
-
Patent number: 8242099Abstract: Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 ?g/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 ?g/ml dexamethasone for at least about three weeks.Type: GrantFiled: October 12, 2011Date of Patent: August 14, 2012Assignee: Allergan, Inc.Inventors: Vernon G. Wong, Mae W. L. Hu
-
Patent number: 8231892Abstract: A drug delivery system (DDS) comprised of segmented biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The segmented implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 50 days and one year, or longer, and permit the DDS to have segments that possess individual and different drug release characteristics.Type: GrantFiled: May 24, 2007Date of Patent: July 31, 2012Assignee: Allergan, Inc.Inventors: Robert T. Lyons, James A. Burke, Michael R. Robinson
-
Patent number: 8206736Abstract: Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.Type: GrantFiled: February 8, 2008Date of Patent: June 26, 2012Assignee: Allergan, Inc.Inventor: Patrick M. Hughes
-
Patent number: 8206737Abstract: Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.Type: GrantFiled: February 8, 2008Date of Patent: June 26, 2012Assignee: Allergan, Inc.Inventor: Patrick M. Hughes
-
Patent number: 8147865Abstract: Biocompatible intraocular implants include a steroid and an auxiliary agent, where the auxiliary agent is present in an amount sufficient to lessen the severity of at least one side effect compared to the use of an otherwise identical implant lacking said auxiliary agent. The steroid and the auxiliary agent may be present on the same intraocular implant or on different implants. The steroid and auxiliary agent may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants containing the steroid and an auxiliary agent may be placed in an eye to treat one or more ocular conditions while reducing the side effects otherwise accompanying steroid use.Type: GrantFiled: June 23, 2006Date of Patent: April 3, 2012Assignee: Allergan, Inc.Inventors: Glenn T. Huang, Thierry Nivaggioli, Lon T. Spada, Hiroshi Sugimoto, Wendy M. Blanda, James N. Chang, Orest Olejnik
-
Patent number: 8119154Abstract: Biocompatible intraocular implants include a steroid and a polymer associated with each other to facilitate release of the steroid into an eye for a period of time greater than about two months. The steroid may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants may be placed in an eye to treat one or more ocular conditions. The steroid is released from the implant for more than about two months, and may be release for more than several years.Type: GrantFiled: April 30, 2004Date of Patent: February 21, 2012Assignee: Allergan, Inc.Inventors: Glenn T. Huang, Thierry Nivaggioli
-
Patent number: 8088407Abstract: Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.Type: GrantFiled: September 7, 2007Date of Patent: January 3, 2012Assignee: Allergan, Inc.Inventor: Vernon G Wong
-
Patent number: 8071120Abstract: Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.Type: GrantFiled: March 30, 2006Date of Patent: December 6, 2011Assignee: Allergan, Inc.Inventor: Vernon G. Wong
-
Patent number: 8063031Abstract: Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 ?g/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 ?g/ml dexamethasone for at least about three weeks.Type: GrantFiled: December 23, 2009Date of Patent: November 22, 2011Assignee: Allergan, Inc.Inventors: Vernon G. Wong, Mae W. L. Hu
-
Patent number: 8048445Abstract: The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.Type: GrantFiled: July 15, 2008Date of Patent: November 1, 2011Assignee: Allergan, Inc.Inventors: Jane-Guo Shiah, Rahul Bhagat, Wendy M. Blanda, Thierry Nivaggioli, Lin Peng, David Chou, David A. Weber
-
Patent number: 8043628Abstract: Methods for reducing or preventing neovascularization or edema in the eye by implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.Type: GrantFiled: October 31, 2007Date of Patent: October 25, 2011Assignee: Allergan, Inc.Inventor: Vernon G. Wong
-
Patent number: 8034366Abstract: The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.Type: GrantFiled: October 31, 2007Date of Patent: October 11, 2011Assignee: Allergan, Inc.Inventors: Jane-Guo Shiah, Rahul Bhagat, Wendy M. Blanda, Thierry Nivaggioli, Lin Peng, David Chou, David A. Weber